Oxinas Partners Wealth Management LLC Sells 879 Shares of Pfizer Inc. (NYSE:PFE)

Oxinas Partners Wealth Management LLC cut its stake in shares of Pfizer Inc. (NYSE:PFE) by 8.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 9,354 shares of the biopharmaceutical company’s stock after selling 879 shares during the period. Oxinas Partners Wealth Management LLC’s holdings in Pfizer were worth $260,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of PFE. Teza Capital Management LLC bought a new position in Pfizer in the 3rd quarter worth about $347,000. Hodges Capital Management Inc. bought a new position in shares of Pfizer in the third quarter worth approximately $203,000. Truist Financial Corp raised its stake in Pfizer by 1.9% in the third quarter. Truist Financial Corp now owns 3,994,764 shares of the biopharmaceutical company’s stock valued at $132,506,000 after purchasing an additional 74,746 shares in the last quarter. Advisors Asset Management Inc. lifted its position in Pfizer by 2.8% during the third quarter. Advisors Asset Management Inc. now owns 564,577 shares of the biopharmaceutical company’s stock valued at $18,727,000 after purchasing an additional 15,507 shares during the last quarter. Finally, Axxcess Wealth Management LLC grew its stake in Pfizer by 178.3% in the 3rd quarter. Axxcess Wealth Management LLC now owns 181,425 shares of the biopharmaceutical company’s stock worth $6,018,000 after buying an additional 116,243 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on PFE shares. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Wednesday, June 26th. BMO Capital Markets reissued an “outperform” rating and set a $36.00 price objective (up from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Finally, Morgan Stanley upped their target price on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 2nd. Nine equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, Pfizer presently has a consensus rating of “Hold” and an average price target of $35.54.

Pfizer Trading Down 1.4 %

Shares of PFE stock traded down $0.39 during trading hours on Tuesday, reaching $27.83. The company’s stock had a trading volume of 21,710,519 shares, compared to its average volume of 40,642,027. The company has a current ratio of 1.05, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66. The firm’s fifty day simple moving average is $27.93 and its 200 day simple moving average is $27.70. The stock has a market capitalization of $157.70 billion, a P/E ratio of -464.76, a P/E/G ratio of 1.10 and a beta of 0.69. Pfizer Inc. has a one year low of $25.20 and a one year high of $37.80.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The company had revenue of $14.88 billion for the quarter, compared to analysts’ expectations of $13.87 billion. During the same quarter in the previous year, the company earned $1.23 earnings per share. Pfizer’s quarterly revenue was down 19.5% on a year-over-year basis. Equities research analysts expect that Pfizer Inc. will post 2.38 EPS for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, July 26th will be paid a $0.42 dividend. The ex-dividend date is Thursday, July 25th. This represents a $1.68 annualized dividend and a yield of 6.04%. Pfizer’s payout ratio is -2,799.53%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.